Kinross supports launch of COVID-19 clinical trial

Kinross recently provided a $100,000 donation to Sunnybrook Health Sciences Centre in Toronto to help launch a promising pan-Canadian-COVID-19 clinical trial. We joined a community of donors who have raised over $1 million towards the Convalescent Plasma for COVID-19 Research (CONCOR-1) trial.

CONCOR-1 will investigate the therapeutic use of plasma (portion of blood containing antibodies) from patients who have recovered from COVID-19 with hopes of proving that antibodies found in the plasma can bind to and neutralize the virus causing COVID-19. 

 “At this critical time, with so many people infected in Canada, donor support is extremely timely,” says Dr. Andy Smith, Sunnybrook’s President and CEO. “Our community clearly recognizes that we have a small window of opportunity to collect and test as much plasma as possible. Donor support is equipping Sunnybrook’s team to lead Canada’s efforts in what is truly a global battle. We thank them for joining us in the fight.”

The trial will enroll 1,200 patients from medical centres across Canada and approximately 650 plasma donors. The plasma collected from blood donors will be injected into patients with active cases of COVID-19 as a potential treatment.

To learn more about the clinical trial, view the news release here.